Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Albert Y Liu

Showing results (81-90 of 92) with videos related to

Pageof 10
Sort By:
Journal of the International AIDS Society|June 12, 2021
Phase 1 pharmacokinetics and safety study of extended duration dapivirine vaginal rings in the United StatesAlbert Y Liu, Clara Dominguez Islas, Holly Gundacker, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|December 16, 2014
High interest in preexposure prophylaxis among men who have sex with men at risk for HIV infection: baseline data from the US PrEP demonstration projectStephanie E Cohen, Eric Vittinghoff, Oliver Bacon, et al.
AIDS Research and Human Retroviruses|March 3, 2017
Differences in Cumulative Exposure and Adherence to Tenofovir in the VOICE, iPrEx OLE, and PrEP Demo Studies as Determined via Hair ConcentrationsCatherine A Koss, Peter Bacchetti, Sharon L Hillier, et al.
ACS Pharmacology & Translational Science|July 5, 2022
Correction to "Identification of Novel UGT1A1 Variants Including UGT1A1 454C>A through the Genotyping of Healthy Participants of the HPTN 077 Study"Herana Kamal Seneviratne, Allyson N Hamlin, Sue Li, et al.
ACS Pharmacology & Translational Science|February 22, 2021
Identification of Novel UGT1A1 Variants Including UGT1A1 454C>A through the Genotyping of Healthy Participants of the HPTN 077 StudyHerana Kamal Seneviratne, Allyson N Hamlin, Sue Li, et al.
The Lancet. HIV|June 5, 2020
Tail-phase safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in HIV-uninfected adults: a secondary analysis of the HPTN 077 trialRaphael J Landovitz, Sue Li, Joseph J Eron, et al.
JAMA Internal Medicine|November 17, 2015
Preexposure Prophylaxis for HIV Infection Integrated With Municipal- and Community-Based Sexual Health ServicesAlbert Y Liu, Stephanie E Cohen, Eric Vittinghoff, et al.
Plos Medicine|November 9, 2018
Safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in low-risk HIV-uninfected individuals: HPTN 077, a phase 2a randomized controlled trialRaphael J Landovitz, Sue Li, Beatriz Grinsztejn, et al.
AIDS and Behavior|June 10, 2022
Sexual behavior and medication adherence in men who have sex with men participating in a pre-exposure prophylaxis study of combinations of Maraviroc, Tenofovir Disoproxil Fumarate and/or Emtricitabine (HPTN 069/ACTG 5305)Kenneth H Mayer, Krista Yuhas, K Rivet Amico, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|December 18, 2016
MTN-017: A Rectal Phase 2 Extended Safety and Acceptability Study of Tenofovir Reduced-Glycerin 1% GelRoss D Cranston, Javier R Lama, Barbra A Richardson, et al.
Pageof 10

Showing results (81-90 of 92) with videos related to

Sort By:
Pageof 10
Journal of the International AIDS Society|June 12, 2021
Phase 1 pharmacokinetics and safety study of extended duration dapivirine vaginal rings in the United StatesAlbert Y Liu, Clara Dominguez Islas, Holly Gundacker, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|December 16, 2014
High interest in preexposure prophylaxis among men who have sex with men at risk for HIV infection: baseline data from the US PrEP demonstration projectStephanie E Cohen, Eric Vittinghoff, Oliver Bacon, et al.
AIDS Research and Human Retroviruses|March 3, 2017
Differences in Cumulative Exposure and Adherence to Tenofovir in the VOICE, iPrEx OLE, and PrEP Demo Studies as Determined via Hair ConcentrationsCatherine A Koss, Peter Bacchetti, Sharon L Hillier, et al.
ACS Pharmacology & Translational Science|July 5, 2022
Correction to "Identification of Novel UGT1A1 Variants Including UGT1A1 454C>A through the Genotyping of Healthy Participants of the HPTN 077 Study"Herana Kamal Seneviratne, Allyson N Hamlin, Sue Li, et al.
ACS Pharmacology & Translational Science|February 22, 2021
Identification of Novel UGT1A1 Variants Including UGT1A1 454C>A through the Genotyping of Healthy Participants of the HPTN 077 StudyHerana Kamal Seneviratne, Allyson N Hamlin, Sue Li, et al.
The Lancet. HIV|June 5, 2020
Tail-phase safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in HIV-uninfected adults: a secondary analysis of the HPTN 077 trialRaphael J Landovitz, Sue Li, Joseph J Eron, et al.
JAMA Internal Medicine|November 17, 2015
Preexposure Prophylaxis for HIV Infection Integrated With Municipal- and Community-Based Sexual Health ServicesAlbert Y Liu, Stephanie E Cohen, Eric Vittinghoff, et al.
Plos Medicine|November 9, 2018
Safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in low-risk HIV-uninfected individuals: HPTN 077, a phase 2a randomized controlled trialRaphael J Landovitz, Sue Li, Beatriz Grinsztejn, et al.
AIDS and Behavior|June 10, 2022
Sexual behavior and medication adherence in men who have sex with men participating in a pre-exposure prophylaxis study of combinations of Maraviroc, Tenofovir Disoproxil Fumarate and/or Emtricitabine (HPTN 069/ACTG 5305)Kenneth H Mayer, Krista Yuhas, K Rivet Amico, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|December 18, 2016
MTN-017: A Rectal Phase 2 Extended Safety and Acceptability Study of Tenofovir Reduced-Glycerin 1% GelRoss D Cranston, Javier R Lama, Barbra A Richardson, et al.
Pageof 10